Stock Events

Stock Events

Telix Pharmaceuticals 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19FebExpected
Q4 2025
-0.01
0
0.02
0.03
Expected EPS
0.0278290131
Actual EPS
-0.00985188

People Also Follow

This list is based on the watchlists of people on Stock Events who follow T3X.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alternative Access First Priority CLO Bond
AAA
Mkt Cap0
Advanced Accelerator Applications, a Novartis company, competes in the radiopharmaceuticals market for diagnostic and therapeutic applications, similar to Telix's focus area.
ClearPoint Neuro
CLPT
Mkt Cap278.74M
ClearPoint Neuro, Inc. specializes in precision delivery of therapeutics to the brain, competing in the neuro-oncology segment where Telix also operates.
Novartis
NVS
Mkt Cap297.32B
Novartis AG, through its acquisitions and internal development, competes across a broad range of therapeutic areas including those targeted by Telix's radiopharmaceuticals.
Bausch Health Companies
BHC
Mkt Cap1.99B
Bausch Health Companies Inc. has a diverse portfolio that includes products competing in the oncology and radiopharmaceutical sectors.
Protagonist Therapeutics
PTGX
Mkt Cap6.62B
Protagonist Therapeutics, Inc. is involved in the development of peptide-based therapeutics, competing in the innovative treatment space including cancer, where Telix is also active.
Dr. Reddy`s Laboratories
RDY
Mkt Cap11.12B
Dr. Reddy’s Laboratories Ltd. manufactures and markets a wide range of pharmaceuticals globally, including generic versions of drugs that compete with Telix's offerings.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol-Myers Squibb Company operates in the oncology space with a broad portfolio of drugs that compete with Telix Pharmaceuticals in the cancer treatment market.
Lilly(Eli) &
LLY
Mkt Cap837.36B
Eli Lilly and Company has a strong presence in oncology and radiopharmaceuticals, directly competing with Telix in several therapeutic areas.
Pfizer
PFE
Mkt Cap161.09B
Pfizer Inc. is a global pharmaceutical giant with a diverse portfolio, including oncology and radiopharmaceuticals, making it a competitor in multiple areas relevant to Telix.

About

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Show more...
CEO
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D
Employees
415
Country
United States
ISIN
AU000000TLX2

Listings

MX
MX
TLX1N.MX
F
DE
T3X0.F
MU
DE
T3X.MU
STU
DE
T3X.STU

0 Comments

Share your thoughts

FAQ

What is Telix Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Telix Pharmaceuticals stocks are traded under the ticker T3X.MU.
When is the next Telix Pharmaceuticals earnings date?▼
Telix Pharmaceuticals is going to release the next earnings report on August 20, 2026.
What were Telix Pharmaceuticals earnings last quarter?▼
T3X.MU earnings for the last quarter are -0.01 EUR per share, whereas the estimation was 0.03 EUR resulting in a -135.4% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Telix Pharmaceuticals have?▼
As of April 12, 2026, the company has 415 employees.
In which sector is Telix Pharmaceuticals located?▼
Telix Pharmaceuticals operates in the Health & Wellness sector.
When did Telix Pharmaceuticals complete a stock split?▼
Telix Pharmaceuticals has not had any recent stock splits.
Where is Telix Pharmaceuticals headquartered?▼
Telix Pharmaceuticals is headquartered in North Melbourne, United States.